LIMNW
MaterialsLiminatus Pharma Inc Warrants
$0.06-0.01 (-12.75%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LIMNW Today?
No stock-specific AI insight has been generated for LIMNW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$465,680.4
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding7.7M
LIMNW News
8 articles- Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking AntibodyYahoo Finance·Mar 17, 2026
- Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public OfferingYahoo Finance·Feb 17, 2026
- BC-Most Active StocksYahoo Finance·Feb 9, 2026
- Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic CooperationYahoo Finance·Oct 30, 2025
- BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled OptimismCoindesk·Aug 5, 2025
- Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital StrategiesYahoo Finance·Jul 25, 2025
- Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital StrategyYahoo Finance·Jul 24, 2025
- Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury StrategyYahoo Finance·Jul 22, 2025
All 8 articles loaded
Price Data
Open$0.00
Previous Close$0.07
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$465,680.4
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding7.7M
About Liminatus Pharma Inc Warrants
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—